PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
HMI Medical Strengthens Diagnostic Capabilities to Support Singapore's Shift Beyond Hospital Care
With the addition of Lifescan Imaging, HMI Medical now operates a network of seven diagnostic and imaging centres, enhancing access to timely diagnosis while supporting coordinated patient care across ...
2026-08-13T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis
SHANGHAI , Aug. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the Investigational New Drug (IND) application for AK0406 injection, the company's ...
2026-08-13T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Bringing K-Aesthetics to Australia: PharmaResearch Showcases REJURAN® at Aesthetics 2026
Following REJURAN ® 's TGA approval in 2023, the company hosted scientific sessions and a clinical masterclass for Australian healthcare professionals. ...
2026-08-13T    Biotechnology   Cosmetics & Personal Care   Medical Equipment   Medical/Pharmaceuticals 
VITAMIN ANGELS EXPANDS PARTNERSHIP WITH THE MINISTRY OF HEALTH OF INDONESIA TO STRENGTHEN NATIONWIDE VITAMIN A CAMPAIGN
Collaboration strengthened health worker training, communication strategies, monitoring and evaluation, and delivered 870,000 vitamin A capsules for children across Indonesia. ...
2026-08-13T    Education   Health Care/Hospital   Medical/Pharmaceuticals 
Osara Health Marks 10 Years with Global Call to Make Cancer Support Beyond Treatment Standard
Launched to mark the company's 10th anniversary, Osara Health's Global Cancer Support Declaration has already secured signatures from healthcare professionals worldwide. ...
2026-08-12T    Computer/Electronics   Health Care/Hospital   Medical/Pharmaceuticals 
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
NANJING, China , Aug. 12, 2026 /PRNewswire/ -- August 6,  the NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO ® ...
2026-08-12T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks
CAMBRIDGE, Mass. , Aug. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company , today ...
2026-08-12T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Beyang Closes Oversubscribed $30 Million Series A Financing
Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor ...
2026-08-12T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Beyang Closes Oversubscribed $30 Million Series A Financing
Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor ...
2026-08-12T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Senhwa's CX-5461 Opens a New Frontier in Photoimmunotherapy; Multinational Study Published in Nucleic Acids Research
TAIPEI and SAN DIEGO , Aug. 12, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. ( TPEx : 6492) today announced a significant research advance involving its investigational drug Pidnarulex (CX-5461). ...
2026-08-12T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.